Non Hodgkin Lymphoma Clinical Trial

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Summary

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To determine whether the addition of plerixafor improves the proportion of patients with lymphoma who collect >= 8 x 10^6 cluster of differentiation (CD)34+ cells/kg within two days by 25% compared to the historical estimate of 42% with etoposide and G-CSF (filgrastim).

II. To determine whether patients achieving collection of >= 8 x 10^6 CD34+ cells/kg have a 15% one year survival advantage relative to the historical estimate of 68% among patients mobilizing >= 2 but < 8 x 10^6 CD34+ cells/kg with etoposide and G-CSF.

SECONDARY OBJECTIVES:

I. To demonstrate that patients receiving >= 8 x 10^6 CD34+ cells/kg have more rapid neutrophil and platelet recovery and earlier hospital discharge than those receiving < 8 x 10^6 CD 34+ cells/kg.

II. To compare overall survival and progression-free survival between patients receiving >= 8 x 10^6 CD34+ cells/kg and those receiving < 8 x 10^6 CD34+ cells/kg.

III. To compare number of days of apheresis required to achieve goal, transfusion requirements, hospitalization costs, need for remobilization between groups.

IV. To evaluate whether peripheral CD34+ cell count correlates with graft content of CD34+ cells.

OUTLINE:

Patients receive etoposide intravenously (IV) over 4 hours on day 0, filgrastim subcutaneously (SC) once daily (QD) beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.

After completion of study treatment, patients are followed up at 28 days and then for at least 1 year.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have biopsy-confirmed non-Hodgkin lymphoma, of any type
Must be eligible for autologous transplantation according to institutional guidelines
Eastern Cooperative Oncology Group performance status of 0 or 1
Karnofsky performance status of 70 to 100
Negative for human immunodeficiency virus (HIV)

prior to the start of mobilization, subjects must have:

Absolute neutrophil count of >= 1.2 x 10^9/L
Platelet count of >= 100 x 10^9/L
Creatinine clearance >= 30 mL/minute
All patients must be able to comprehend and sign informed consent
If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy

Exclusion Criteria:

Have had previous transplants and/or prior mobilization attempts
Have evidence of progressive non-Hodgkin lymphoma
Have evidence of bone marrow involvement of lymphoma at time of transplant staging
Had evidence of active central nervous system (CNS) involvement
Have had previous radiation of the pelvic area
Have had prior radioimmunotherapy
Have received experimental therapy within 2 weeks of enrollment
Be currently enrolled in another investigational protocol
Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

25

Study ID:

NCT01408043

Recruitment Status:

Terminated

Sponsor:

Case Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland Ohio, 44195, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

25

Study ID:

NCT01408043

Recruitment Status:

Terminated

Sponsor:


Case Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider